Description：ELISA for the detection of bispecific antibody Nivatrotamab in human serum and plasma.
Lead time for this kit is 5 weeks.
About the kit： - Uses anti-idiotypic monoclonal antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity.
- Recovery rates are between 85 - 115％ - Validated as per US FDA guidelines for Bioassays - Developed using the innovator drug as calibrator - Shelf life： 1 year.Nivatrotamab is a monoclonal anti-GD2_CD3 bispecific antibody being investigated for small-cell lung cancer （SCLC） therapy as well as in other solid tumors.
From Y-mabs therapeutics： Nivatrotamab is being developed with the goal of bringing highly potent T cells to directly kill GD2-expressing tumor cells.
It is the first T-cellPengaging antibody utilizing the BiClone format to enter human clinical trials.
The BiClone format utilizes an IgG-scFv format to maximize tumor binding and T-cell recruitment and minimize risk of non-specific T-cell engagement.
仕様
サイズ：1 x 96 wells
Reactivity：Human
アプリケーション：ELISA,Immunoassay
Sensitivity：Please refer to the current IFU for the updated calibrator range and sensitivity.
